Browse AUP1

Summary
SymbolAUP1
Nameancient ubiquitous protein 1
Aliases
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass type III membrane protein Cytoplasmic side
Domain PF02845 CUE domain
Function

May play a role in the translocation of terminally misfolded proteins from the endoplasmic reticulum lumen to the cytoplasm and their degradation by the proteasome.

> Gene Ontology
 
Biological Process GO:0010498 proteasomal protein catabolic process
GO:0030433 ER-associated ubiquitin-dependent protein catabolic process
GO:0030970 retrograde protein transport, ER to cytosol
GO:0032527 protein exit from endoplasmic reticulum
GO:0034976 response to endoplasmic reticulum stress
GO:0036503 ERAD pathway
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:1903513 endoplasmic reticulum to cytosol transport
Molecular Function GO:0032182 ubiquitin-like protein binding
GO:0043130 ubiquitin binding
GO:0055103 ligase regulator activity
GO:0055106 ubiquitin-protein transferase regulator activity
GO:0097027 ubiquitin-protein transferase activator activity
Cellular Component GO:0000151 ubiquitin ligase complex
GO:0000153 cytoplasmic ubiquitin ligase complex
GO:0000835 ER ubiquitin ligase complex
GO:0000836 Hrd1p ubiquitin ligase complex
GO:0000839 Hrd1p ubiquitin ligase ERAD-L complex
GO:0030176 integral component of endoplasmic reticulum membrane
GO:0031227 intrinsic component of endoplasmic reticulum membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolAUP1
Nameancient ubiquitous protein 1
Aliases
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AUP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolAUP1
Nameancient ubiquitous protein 1
Aliases
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AUP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 1.93; FDR: 0.000150 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolAUP1
Nameancient ubiquitous protein 1
Aliases
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AUP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0940.724
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.270.934
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0350.988
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2690.36
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1010.962
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4830.863
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0170.969
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1180.951
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0830.969
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1630.939
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3630.908
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0580.336
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AUP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAUP1
Nameancient ubiquitous protein 1
Aliases
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AUP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAUP1
Nameancient ubiquitous protein 1
Aliases
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AUP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AUP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAUP1
Nameancient ubiquitous protein 1
Aliases
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AUP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAUP1
Nameancient ubiquitous protein 1
Aliases
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AUP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAUP1
Nameancient ubiquitous protein 1
Aliases
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AUP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAUP1
Nameancient ubiquitous protein 1
Aliases
Chromosomal Location2p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AUP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.